Shamburg News · 8-K filed Nov 16, 2026, 4:16 PM EST
AEON Biopharma Reports Third Quarter 2026 Financial Results and Corporate Update
AEON · AEON Biopharma, Inc.
- Earnings
- Financial statements
- Other event
- Materiality: high
AEON Biopharma reported net income of $2,465 thousand, or $0.01 per basic and diluted share, for the third quarter ended September 30, 2026, compared with a net loss of $4,538 thousand a year earlier. The company reported cash and cash equivalents of $11.4 million as of September 30, 2026, and about $6.2 million in gross proceeds from milestone warrant exercises received by November 16, 2026. It expects these resources to fund operations into the second quarter of 2027.
Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001837607-26-000087.
Written from the filing by Shamburg Markets. Figures are as reported by the company.